Phibro Animal Health Announces New Regulatory Framework in Brazil
Phibro Animal Health "announced expected implementation of a new regulatory framework governing the use of certain antimicrobials in Brazil that have growth promotion indications. The Brazilian Ministry of Agriculture and Livestock published Ordinance No. 1617 on April 27, 2026, prohibiting the importation, manufacture, marketing and use of performance enhancing feed additives containing antimicrobials classified as important in human or veterinary medicine, including virginiamycin and bacitracin. This regulation brings Brazil into alignment with regulatory approaches adopted in other global markets. This prohibition will come into effect after a transition period of 180 days from the date of the Ordinance, during such times companies and customers may continue to use and sell the products under their current labels. Phibro is working cooperatively with MAPA and relevant industry associations to support an orderly transition. The Company has been actively engaged with MAPA on new registrations of virginiamycin for therapeutic use in cattle and broiler chickens. These registrations are in the final stages of review and approval by MAPA and are expected during the transition period. Phibro's bacitracin product already carries therapeutic claims in Brazil. Under the new regulatory framework, following the transition period, use of the subject antimicrobials will require a veterinary prescription. To support compliance and operational efficiency, Phibro is making available to the Brazilian market PhibroVet(R), a digital platform designed to facilitate the creation, transmission, and management of veterinary prescriptions and prescription history. Based on the 180 day transition period, the Company expects the regulatory change to have limited impact on its fiscal year 2026 results."
